<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728101</url>
  </required_header>
  <id_info>
    <org_study_id>SD-DDI</org_study_id>
    <nct_id>NCT03728101</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Simvastatin and Dabigatran</brief_title>
  <official_title>A Clinical Trial to Evaluate the Effect of Simvastatin on the Pharmacokinetics and Pharmacodynamics of Dabigatran in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of simvastatin on the pharmacokinetics and
      pharmacodynamics of dabigatran in healthy male adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics and pharmacodynamics of dabigatran without coadministration of simvastatin
      will be compared with those after multiple administration of simvastatin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">December 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>24 hours, zero to infinite</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aPTT</measure>
    <time_frame>24 hours</time_frame>
    <description>Activated partial thromboplastin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TT</measure>
    <time_frame>24 hours</time_frame>
    <description>Thrombin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lag time</measure>
    <time_frame>24 hours</time_frame>
    <description>thrombin generation assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak thrombin</measure>
    <time_frame>24 hours</time_frame>
    <description>thrombin generation assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>velocity index</measure>
    <time_frame>24 hours</time_frame>
    <description>thrombin generation assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve</measure>
    <time_frame>24 hours</time_frame>
    <description>thrombin generation assay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate
Simvastatin + Dabigatran etexilate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin, Dabigatran Etexilate</intervention_name>
    <description>The subjects receive dabigatran etexilate with and without simvastatin administration</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 19 and 50 years

          -  Subjects with body mass index (BMI) between 18.5 and 29.9 kg/m2 and weight more than
             50 kg

          -  Subjects who agree with performing contraception during the study

          -  Subjects who agreed with written informed consent

        Exclusion Criteria

          -  Subjects who have a current or prior history of cardiovascular, respiratory, hepatic,
             renal, hematological, gastrointestinal, endocrine, immunologic, skin, psychiatric, or
             neurological diseases that is clinically significant

          -  Subjects who have clinically significant allergic history or allergy to simvastatin,
             dabigatran, or other components of drug

          -  Creatinine clearance is below 60 ml/min

          -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) is more than 2-fold
             of upper limit or normal range

          -  Subjects who have clinically significant bleeding

          -  Subjects at risk of bleeding

          -  Subjects who took drugs which significantly interact with simvastatin or dabigatran
             prior to dosing

          -  Whole blood donation within 60 days prior to dosing, or apheresis donation within 20
             days prior to dosing

          -  Participated in a previous clinical trial within 90 days prior to dosing

          -  Subjects with a history of alcohol abuse

          -  Subjects who are determined by investigator's decision as unsuitable for clinical
             trial participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyewon Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Instructor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>March 9, 2019</last_update_submitted>
  <last_update_submitted_qc>March 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Hyewon Chung</investigator_full_name>
    <investigator_title>Clinical instructor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

